osteoporosis
Conditions
Interventions
Observation group:no
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) Fully understand the pros and cons of various anti-osteoporosis drugs, voluntarily choose denosumab treatment, are willing to supplement calcium and vitamin D, and voluntarily participate in this study (2) Shanghai women of Han nationality aged 50-80 with natural menopause for at least 1 year. (3) There are no severe lumbar anatomical abnormalities that affect DXA bone mineral density measurement, such as severe scoliosis. (4) Meet the diagnostic criteria of osteoporosis in the "Guidelines for the Diagnosis and Treatment of Primary Osteoporosis (2017)" (meet any 1 item): ?The bone density of the lumbar vertebrae 1-4 or the neck of the femur or the total hip is lower than that of the youth The 2.5SD of women peak bone density is the standard for osteoporosis; ?There is a fragility fracture, after 50 years of age, of the hip or vertebral body caused by minor trauma (injury strength equals fall from standing height); ?Lumbar vertebra 1- 4 Or femoral neck or total hip bone density is between -1 to -2.5 peak bone mineral density in young women, and there are fragility fractures of the proximal humerus or pelvis or distal forearm. (5) Understand the process of this study, have good compliance, and are willing to follow up regularly.
Exclusion criteria
Exclusion criteria: (1) Severe cardiovascular diseases: such as myocardial infarction, unstable angina, severe arrhythmia, etc; (2) Chronic liver disease, abnormal liver function (ALT>1.5 times the upper limit of normal); renal insufficiency (creatinine clearance rate 7.0mmol/L), etc.; (8) Bone mineral diseases: such as hypoparathyroidism or hyperthyroidism, deformed osteitis, osteogenesis imperfecta, osteomalacia, etc; (9) Blood system disorders: such as leukopenia ( 3 months (including any type of bisphosphonate drugs, estrogen receptor modulators, estrogen, active vitamin D, etc.); (15) Previous use of intramuscular injection or nasal spray of calcitonin for> 3 months; (16) Received RANKL inhibitor, or intravenous bisphosphonates in the past 5 years; (17) Those who have used parathyroid hormone in the past.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BMD; | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone turnover index; | — |
Countries
china
Contacts
Public ContactJiemei Gu
Shanghai Sixth People's Hospital
Outcome results
None listed